Safety and Efficacy Study of the First Domestically Produced FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter Therapy for Rapid Arrhythmia With Tissue Temperature Measurement Function

1\. Inclusion Criteria 1. Patient age between 18 and 75 years old, male or non-pregnant female; 2. Confirmed diagnosis of supraventricular tachycardia or atrial fibrillation requiring catheter radiofrequency ablation surgery; 3. Signed informed consent form approved by the ethics committee; 4. Willingness to undergo follow-up and evaluation as required by the protocol. 2\. Exclusion Criteria Include: 1. Exclusion criteria for atrial fibrillation patients: Patients should not participate in this study if any of the following conditions apply: * Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%; * Left atrial thrombus; * History of atrial septal repair or atrial myxoma; * History of cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack); * Cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision); * Acute or severe systemic infection; * Severe liver or kidney disease; * Significant bleeding tendency or haematological disorders; * Patients with other conditions deemed inappropriate for participation in this trial by the investigators. 2. Exclusion criteria for patients with ventricular tachycardia and supraventricular tachycardia: Patients should not participate in this study if any of the following conditions apply: * Left atrial size ≥50 mm and left ventricular ejection fraction ≤40%; * History of atrial septal defect repair or atrial myxoma; * Patients with cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack); * Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision); * Patients with acute or severe systemic infection; * Patients with severe liver or kidney disease; * Patients with a significant tendency to bleed or haematological disorders; * Patients with other conditions deemed by the investigator to be unsuitable for participation in this trial.